نتایج جستجو برای: relapsed hodgkin lymphoma
تعداد نتایج: 117560 فیلتر نتایج به سال:
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after...
Phase 1 testing of SGN-30, a chimeric monoclonal antibody for the treatment of CD30 malignancies, was conducted in a multicenter study. To explore the safety profile and establish the maximum tolerated dose (MTD), 24 patients with refractory or relapsed Hodgkin lymphoma or CD30 nonHodgkin lymphoma received 6 weekly doses of intravenous SGN-30 at 4 dose levels (2, 4, 8, or 12 mg/kg). Serum conce...
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequa...
objective(s): the aim of this study is to evaluate the role of pet-ct in identification of different patterns of extranodal involvement in hodgkin’s disease (hd) and non-hodgkin’s lymphoma (nhl) and to enlist the common sites of extranodal involvement in each histological type and compare our results with the existing literature. methods: in this retrospective study of 281 cases of lymphomas of...
Background: The aim of this study was to perform cost-effectiveness Analysis of IEV versus ESHAP chemotherapy regimen in patients with Lymphoma in Iran. Materials and Methods: Our study used a cross-sectional design done as a double-blind study of 65 patients suffering from relapsed/refractory Hodgkin and non-Hodgkin's Lymphoma in Amir Oncology Hospital in Shiraz, in the south of Iran. The cost...
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL/T) groups, the response rates were...
There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has recently been approved for treatment of these patients. Bendamustine is a uniquely structured alkylating agent that lacks cross-resistance with other alkylators. This agent has a high degree of activity against a variety of tumo...
Primary central nervous system lymphoma (PCNSL) is a rare disease which accounts for 1–2 % of non-Hodgkin lymphoma and 3–5 % of primary brain tumor lesions. PCNSL of an immunocompetent patient is an uncommon disease, it is estimated at 4 % of new diagnoses of CNS tumors. The prognosis of PCNSL is poor compared to other extranodal lymphomas, with a 5-year survival estimated between 20 and 40 %. ...
Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma. Paraneoplastic disease with central nervous system involvement is a rare complication. Immunosuppression for the paraneoplastic features and chemotherapy for the underlying malignancy are described treatments but benefits are often short-lived because of co-morbid complications and disease resistance. This report descri...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید